Dehydroepiandrosterone-Sulfate, Insulin Resistance and Ovarian Volume Estimation in Patients With Polycystic Ovarian Syndrome

Chrysi Christodoulaki; M.D., Eftihios Trakakis; M.D.- Ph.D., Vasilios Pergialiotis; M.D.- Ph.D., Periklis Panagopoulos; M.D.- Ph.D., Charalambos Chrelias; M.D.- Ph.D., Dimitrios Kassanos; M.D.- Ph.D., Dimos Sioutis; M.D.- Ph.D., Nikolaos Papantoniou; M.D.- Ph.D., Dimitrios Xirofotos; M.D.- Ph.D.

The Third Department of Obstetrics and Gynaecology, Attiko Hospital, National and Kapodistrian University of Athens, Athens, Greece

Received February 2017; Revised and accepted March 2017

Abstract

Objective: To investigate the potential association of DHEA-S with metabolic and hormonal alterations and with disorders of ovarian morphology.

Materials and methods: The present study was based on women with PCOS that attended the Gynaecological Endocrinology – Paediatric and Adolescence Endocrinology Department of our clinic. Overall, 321 patients who met the Rotterdam ESHRE/ASRM – Sponsored criteria for the definition of PCOS were included. Women’s personal medical history was recorded, anthropometric parameters were assessed and blood was drawn for analysis of metabolic and hormonal parameters. A gynaecological ultrasound was also performed to evaluate ovarian morphology.

Results: Correlation analysis revealed a significant negative correlation of DHEA-S with the mean volume of the right and left ovary and with the maximum volume of the largest ovary. This finding remained significant after adjusting for age and BMI (β ± SE = -0.39 ± 0.17, p = 0.023 in the case of mean ovarian volume and β ± SE = -0.36 ± 0.17, p = 0.032 in the case of the maximum volume of the maximum ovarian volume).

Conclusion: The findings of our study reveal a clear negative association of DHEA-S with ovarian volume. To date, however, current evidence in this field are restricted to experimental animal models. Future clinical studies are needed in this field to corroborate our findings.

Keywords: DHEA-S; PCOS; Ovary; Androgens; Ovarian Volume

Introduction

Polycystic Ovary Syndrome (PCOS) is the most common endocrine disorder in reproductive age women with an incidence that ranges between 6-17%. (1-3). Its diagnosis is based on the presence of at least two out of the three following features: oligo or anovulation, clinical and/or biochemical hyperandrogenism and polycystic ovarian morphology on ultrasound evaluation (4, 5). PCOS is correlated with a diposity and insulin resistance (6, 7). Insulin resistance leads to hyperinsulinemia which triggers an overstimulation of ovarian theca cells, that concurrently, leads to increased androgen
secretion and decreased production of sex hormone binding globulin (8, 9).

Ovaries and adrenal glands share the same pathway of steroid hormone production. Dehydroepiandrosterone (DHEA) and especially its sulphate ester (DHEA-S) are mainly produced in the adrenal glands (90% of the total circulating amount). Although, approximately 40-70% of women with PCOS have increased levels of Δ4-Androstenedione and DHEA-S, the exact mechanism that triggers the production of androgens from the adrenal gland still remains unclear (10, 11). The correlation between DHEA-S with insulin resistance and glucose metabolism has not been thoroughly examined. Buyalos et al showed that acute induced hyperinsulinemia levels did not affect DHEA-S levels in obese and non-obese women with or without PCOS (12).

Recent studies have shown that insulin can increase DHEA-S production (13). On the contrary, in other studies DHEA-S is positively correlated to improved insulin resistance in such female population (14).

Furthermore, DHEA seems to positively influence the antral follicle count and ovarian volume of women undergoing assisted reproduction for primary insufficiency (15). To date however, a clear association of DHEA-S with ovarian morphology in PCOS women has not been proven.

Based on all these data the aim of our study was to investigate the correlation between DHEA-S, insulin resistance, glucose metabolism and ovarian volume in a Greek female population with PCOS.

Materials and methods

Patients: We designed a prospective study which took place in the Gynaecological Endocrinology – Paediatric and Adolescence Endocrinology Department Outpatient Clinic of the Third Department of Obstetrics and Gynaecology, “ATTIKON” University Hospital between January 2007 and December 2015. All patients with PCOS symptomatology were considered to be eligible for participation in the present study. Initially, 367 patients were screened. The study was approved by the Institution Ethics Committee. After baseline assessment 321 patients who met the Rotterdam ESHRE/ ASRM – Sponsored PCOS criteria were included in the study (4). Patients with a prior history of underlying conditions that could cause hyperandrogenemia or ovarian dysfunction (congenital adrenal hyperplasia, Cushing syndrome, malignancies or medication, thyroid disorders and hyperprolactinemia) were excluded. Patients who refused to participate in the present study were also excluded.

A detailed medical history was obtained from all patients. Relevant data regarding age, menstrual cycle, oligo or anovulation or other menstrual disorders, subfertility history, concomitant medical disorders (e.g. thyroid or adrenal diseases, diabetes mellitus etc.), medication (e.g. COCs, hormones etc.), nutrition and lifestyle habits (e.g. smoking, alcohol consumption) and family medical history was recorded.

Subsequently, the patients were clinically examined and their height, weight and body mass index (BMI) was measured. Additionally, clinical signs and symptoms of hyperandrogenemia such as hirsutism, acne, adiposity and androgenic alopecia were assessed. In the case of hirsutism the Ferriman-Gallwey score was used to evaluate its severity (16).

According to the classification of the modified method hair growth was rated from 0 to 4 (extensive hair growth) in each of nine locations of the body, resulting in a score that varied from a minimum 0 up to a maximum score of 36. For the study population, a score of 60r higher was regarded as indicative of androgen excess.

Laboratory Assessment: Morning fasting blood samples were drawn during the early follicular phase between day 3 and 6 of the menstrual cycle. After centrifugation Follicular Stimulating Hormone(FSH), Luteinizing Hormone(LH), 17-b estradiol (E2), 17OH-progesterone (17OH-P), prolactin (PRL), total testosterone (T), free testosterone (fT), sex hormone binding globulin (SHBG), dehydroepiandrosterone sulphate (DHEAS), Δ4-Androstenedione, cortisol (C), cholesterol (Chol), HDL, LDL, triglycerides (TG), glucose (Glu) and insulin. All women underwent an Oral Glucose Tolerance Test (OGTT) with 75gr glucose to detect impaired glucose tolerance (IGT) and insulin resistance (IR), after a 8-12 h fasting. Impaired insulin tolerance was diagnosed based on the WHO criteria (17). Insulin and glucose levels were tested at 0’, 60’ and 120’. The diagnosis of insulin resistance (IR) was based on the presence of one of the two following criteria: serum insulin levels at 120’ > 100 μIU/ml or serum insulin levels at 120’ ten folds higher than at 0’. Additional indices for the assessment of insulin resistance were also evaluated and these included the Homeostasis Model Assessment for Insulin Resistance (HOMA-IR), Quantitative Insulin Sensitivity

Journal of Family and Reproductive Health  http://jfrh.tums.ac.ir  Vol. 11, No. 1, March 2017  25
Check Index (QUICKI) and Matsuda Index. The calculation formulas for these were the following:

- HOMA-IR: Glucose X Insulin/405
- QUICKI: \(1 / (\log(\text{fasting insulin} \ \mu U/mL) + \log(\text{fasting glucose mg/dL}))\)
- Matsuda Index:

\[\text{ISI}_{\text{MATSUDA}} = \frac{1000}{\sqrt{G_{\text{MEAN}} I_{\text{MEAN}}}}\]

Glucose measurements were performed by the colorimetric method for quantitative measurement of glucose concentration in serum, plasma and urine, (Menarini diagnostics, Firenze, Italy) with coefficients of variance (CV) of 2.33%. Hormone measurements were performed by the ADVIA Centaur Immunoasay System (Siemens, Munich, Germany) for FSH, LH and insulin with CV of 3.9%, 2.7% and 7.5% respectively.

Also measurements of T3, T4, TSH and PRL were performed by the ADVIA Centaur system with CV of 3.44%, 5.55%, 5.87% and 4.8%, respectively. Testosterone, DHEAS and cortisol measurements were performed with the analysis of Elescys 1010/2020 and Modstar analytics E 170 (Roche Diagnostics, Basel, Switzerland) with CV of 5.6%, 6% and 7% respectively. Δ4-A, 17-OHP and free testosterone (FT) measurements were performed with radioimmunoassay kits provided by the Diagnostic Systems Laboratories Inc. (Beckman Coulter, Pasadena, California) with CV of 6.3%, 9.7% and 9.7% respectively.

**Ultrasound assessment:** A transvaginal ultrasound examination was performed between day 6 – 8 to assess ovarian morphology, using a General Electrics Voluson 730 ultrasound machine (General Electrics, Boston, Massachusetts). The scan was performed by a consultant gynaecologist who was specialized in gynecologic ultrasound.

**Statistical analysis:** Continuous variables are presented with mean and standard deviation (SD) or with median and interquartile range (IQR). Quantitative variables are presented with absolute and relative frequencies. Pearson correlation coefficients were used to explore the association of two continuous variables. The association of DHEA-S with with the mean volume of the right and left ovary and with the maximum volume of the largest ovary was further investigated after adjusting for Body Mass Index (BMI) and age using linear regression analysis. Regression coefficients (β) and standard errors (SE) are presented from the results of regression analysis. DHEA-S, HOMA, QUICKI and MATSUDA were log-transformed due to their skewed distribution and also adjusted for BMI and age. All tests were two-tailed. Statistical significance was set at 0.05 and analyses were conducted using SPSS statistical software (IBM Corp. Released 2010, IBM SPSS Statistics for Windows, Version 19.0. Armonk, NY: IBM Corp).

**Results**

Overall 321 PCOS patients were enrolled in the present study. Ten patients requested to be withdrawn from the study in a latter setting. From the remaining, hormonal and biochemical data were available in 303 patients. Table 1 presents the family history and the anthropometric characteristics of enrolled patients. Descriptive statistics for hormonal measurements are shown in table 2. DHEA-S had a significant and negative correlation with with the mean volume of the right and left ovary and with the maximum volume of the largest ovary (Table 3). The association of DHEA-S with with the mean volume of the right and left ovary remained significant after adjusting for age and BMI (β ± SE = -0.39 ± 0.17, p = 0.023). The same was observed when DHEAS was associated with the maximum volume of the largest ovary (β ± SE= -0.36 ± 0.17, p = 0.032). Correlation of DHEAS with HOMA, QUICKI and MATSUDA was not significant as shown in table 3.

**Discussion**

The findings of our study reveal a statistically significant negative correlation between DHEA-S levels and maximum ovarian volume (p-values: 0.008, 0.013 respectively). This correlation was further strengthened by them ultivariate analysis when age and BMI were used as independent variables.

Increased levels of DHEA-S have been previously observed in patients with PCOS and polycystic morphology in ultrasound compared to patients with PCOS without polycystic morphology on ultrasound (18). The negative association of DHEA-S with ovarian volume can be explained by the findings of a previous experimental study that suggested that PCOS rats treated with DHEA demonstrated ovarian hyperfibrosis which resulted in anovulation (19). According to Miao et al. this effect is triggered through activation of TGF-beta1 and CTGF according to findings of previous studies (20). Rosiglitazone treatment postpones this process. However, it remains unknown if this effect is mediated through DHEA down-regulation.
Table 1: Patients’ characteristics

|                                                                 | n    | %     |
|------------------------------------------------------------------|------|-------|
| **Age, (mean ± SD/median (IQR) (321 patients))**                 | 25 ± 5.7 | 25 (21-29) |
| Smokers (304 patients)                                           | 91   | 29.9  |
| Family history of menstrual disorders                           | Free | 279   | 86.9 |
| Mother                                                           | 21   | 6.6   |
| Sister                                                           | 2    | 0.6   |
| Mother and sister                                                | 2    | 0.6   |
| Missing data                                                     | 17   | 5.3   |
| Family history of hyperandrogenemia                             | Free | 286   | 89.0 |
| Mother                                                           | 14   | 4.5   |
| Sister                                                           | 2    | 0.6   |
| Mother and sister                                                | 2    | 0.6   |
| Missing data                                                     | 17   | 5.3   |
| Family history of diabetes mellitus                             | Free | 224   | 69.8 |
| Father                                                           | 43   | 13.4  |
| Mother                                                           | 29   | 9.0   |
| Both parents                                                     | 9    | 2.8   |
| Missing data                                                     | 16   | 5.0   |
| Family history CAD                                               | Free | 231   | 72.0 |
| Mother                                                           | 48   | 14.9  |
| Father                                                           | 19   | 5.9   |
| Both parents                                                     | 8    | 2.5   |
| Missing data                                                     | 15   | 4.7   |
| Personal history                                                 | Free | 278   | 86.7 |
| Hypothyroidism                                                   | 21   | 6.5   |
| Diabetes mellitus                                                | 1    | 0.3   |
| Missing data                                                     | 21   | 6.5   |
| **BMI, mean ± SD median (range) (313 patients)**                 | 25.7 ± 6.8 | 23.4 (20.6-30) |
| **BMI**                                                          |       |       |
| Normal                                                           | 186  | 57.9  |
| Overweight                                                       | 49   | 15.3  |
| Obese                                                            | 78   | 24.3  |
| Missing                                                           | 8    | 2.5   |
| **Menstrual disorders**                                          | 26-35 days | 86 | 26.8 |
| > 35 days                                                        | 180  | 56.0  |
| < 26 days                                                        | 16   | 5.0   |
| Amenorrhea                                                       | 27   | 8.4   |
| Missing data                                                     | 12   | 3.8   |
| **Lorenzo score, mean ± SD/median (IQR)**                       | 9.7 ± 4.0 | 10 (6-12) |
| **Acne**                                                         |       |       |
| No                                                               | 133  | 41.5  |
| Mild                                                              | 159  | 49.5  |
| Severe                                                            | 13   | 4.0   |
| Missing data                                                     | 16   | 5.0   |
| **Androgenic alopecia**                                          | Yes  | 187   | 64.0 |
| **Acanthosis nigricans**                                         | Yes  | 292   | 98.6 |
| **Phenotype**                                                    |       |       |
| Normal                                                           | 272  | 100.0 |
| **Waist circumference, mean ± SD/median (IQR) (303 patients)**   | 90.4 ± 15.9 | 88 (78-100) |
| **Hip circumference, mean ± SD/median (IQR) (303 patients)**     | 79.4 ± 28.8 | 67 (58-106) |
| **Waist to hip circumference, mean±SD/median (IQR) (303 patients)** | 1 ± 0.4 | 0.8 (0.7-1.4) |
| **Mean ovarian volume (303 patients)**                          | 10.7 ± 4.4 | 10.25 (7.7-12.8) |
| **Maximum ovarian volume (303 patients)**                       | 12.1 ± 5.1 | 11.4 (8.3-14.4) |

CAD: congenital adrenal hyperplasia, SD: standard deviation, IQR: interquartile range
We also investigated the correlation between DHEA-S and HOMA, QUICKI and Matsuda indices, but failed to observe any type of association. These findings could underline the difficulty to determine the role of hyperinsulinemia and insulin resistance in the adrenal and ovarian steroidogenesis and especially DHEA-S secretion. Previous studies in the field suggest that DHEA-S is negatively associated with fasting insulin in PCOS patients (14, 21). Goodarzi et al, however, showed that both insulin and glucose do not influence the adrenal precursor androgen excess which can be found in 20-30% of PCOS patients (22).

Table 2: Hormonal assessment of patients (Outcomes from 303 patients)

| Parameter          | Mean ± SD   | Median (IQR) |
|--------------------|-------------|--------------|
| FSH (mU/ml)        | 5.9 ± 2.2   | 5.6 (4.4-6.8) |
| LH (mU/ml)         | 6.4 ± 3.9   | 5.5 (3.8-7.8) |
| PRL                | 18.3 ± 16.9 | 15 (10.5-21.3) |
| E2 (pg/ml)         | 52.2 ± 60.8 | 39.2 (31-53)  |
| Testosterone (ng/dl)| 57.5 ± 25.5 | 59.6 (39-72)  |
| Free testosterone (pg/ml) | 2.2 ± 1.4 | 2 (1.3-2.7)  |
| OHP17 (ng/ml)      | 1.3 ± 0.8   | 1.1 (0.8-1.6) |
| DHEAS (μg/dl)      | 238.4 ± 203.4 | 210 (139-313) |
| Δ4 Androstendione (nmol/L) | 2.6 ± 1.3 | 2.4 (1.8-3.2) |
| SHBG (nmol/L)      | 49.2 ± 34.5 | 41.8 (28.8-61) |
| Cortisol (mg/dl)   | 24.7 ± 35.1 | 18.3 (12.6-23) |
| T3 (nmol/L)        | 3.1 ± 12.9  | 1.4 (1.1-2)   |
| T4 (μg/dl)         | 8.6 ± 9.3   | 7.7 (6.8-8.8) |
| HOMA               | 2.8 ± 3     | 2 (1.2-3)     |
| QUICKI             | 0.3 ± 0     | 0.3 (0.3-0.4) |
| MATSUDA            | 9.9 ± 6.9   | 9 (4.8-13)    |
| TSH (mU/L)         | 2.3 ± 1.6   | 2 (1.3-2.7)   |
| Negative antithyroid antibodies (%) | 50 (86.2)     |

IQR: interquartile range

**Strengths of our study:** The findings of our study are based on a significant number of women that were consecutively recruited on a prospective basis with specific exclusion criteria which limited other potential reasons of DHEA-S excess. For this reason, the possibility of selection bias is low.

**Clinical implications and future research:** In our study DHEA-S levels were associated with reduced mean ovarian volume. The exact reason that influences this observation remains unknown; however, previous studies suggest that DHEA administration in experimental models might lead to ovarian fibrosis. Physicians should take in mind this possible association which might become in the future a useful prognostic tool for patients with PCOS. Future studies are needed, however, in the field to corroborate our findings. These should consistently examine all included parameters. Furthermore, basic research in the field should investigate the underlying pathophysiologic pathways which might interconnect DHEA-S to ovarian morphology.

**Conclusion**

Our observational study clearly shows a negative correlation between DHEA-S and ovarian volume. To date, however, the exact pathophysiology behind this association remains unknown. Experimental studies suggest that this effect might be associated by increased fibrosis of ovarian tissue, which ultimately results in menstrual disorders and decreased fertility potential. Given the fact that this field remains unexplored in a clinical setting, further studies are needed to reach firm conclusions and to investigate in depth the underlying mechanisms.

**Conflict of Interests**

Authors have no conflict of interests.

**Acknowledgments**

None.

**References**

1. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Filandra FA, Tsianetali TC, Spina GG, et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 1999;84:4006-11.
2. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population.
J Clin Endocrinol Metab 2004;89:2745-9.
3. Lauritsen MP, Bentzen JG, Pinborg A, Loft A, Forman JL, Thuesen LL, et al. The prevalence of polycystic ovary syndrome in a normal population according to the Rotterdam criteria versus revised criteria including anti-Müllerian hormone. Hum Reprod 2014; 29: 791-801.
4. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Hum Reprod 2004;19:41-7.
5. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group.. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycysticovary syndrome. Fertil Steril 2004;81:19-25.
6. Sam S, Dunaif A. Polycystic ovary syndrome: syndrome XX? Trends Endocrinol Metab 2003;14:365-70.
7. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006;444:840-6.
8. Gilling-Smith C, Willis DS, Beard RW, Franks S. Hypersecretion of androstenedione by isolated thecal cells from polycystic ovaries. J Clin Endocrinol Metab 1994;79:1158-65.
9. Yucel A, Noyan V, Sagsoz N. The association of serum androgens and insulin resistance with fat distribution in polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2006;126:81-6.
10. Azziz R, Black V, Hines GA, Fox LM, Boots LR. Adrenal androgen excess in the polycystic ovary syndrome: sensitivity and responsibility of the hypothalamic-pituitary-adrenal axis. J Clin Endocrinol Metab 1998;83:2317-23.
11. Ersoy AO, Tokmak A, Ozler S, Oztas E, Ersoy C, Celik HT, et al. Are progranulin levels associated with polycystic ovary syndrome and its possible metabolic effects in adolescents and young women? Arch Gynecol Obstet 2016;294:403-9.
12. Buyalos RP, Bradley EL Jr, Judd HL, Zacur HA, Azziz R. No acute effect of physiological insulin increase on dehydroepiandrosterone sulfate in women with obesity and/or polycystic ovarian disease. Fertil Steril 1991;56:1179-82.
13. Hines GA, Smith ER, Azziz R. Influence of insulin and testosterone on adrenocortical steroidogenesis in vitro: preliminary studies. Fertil Steril 2001;76:730-5.
14. Brennan K, Huang A, Azziz R. Dehydroepiandrosterone sulfate and insulin resistance in patients with polycystic ovary syndrome. Fertil Steril 2009;91:1848-52.
15. Yeung TW, Li RH, Lee VC, Ho PC, Ng EH. A randomized double-blinded placebo-controlled trial on the effect of dehydroepiandrosterone for 16 weeks on ovarian response markers in women with primary ovarian insufficiency. J Clin Endocrinol Metab 2013;98:380-8.
16. FERRIMAN D, GALLWEY JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961;21:1440-7.
17. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539-53.
18. Tena G, Moran C, Romero R, Moran S. Ovarian morphology and endocrine function in polycystic ovary syndrome. Arch Gynecol Obstet 2011;284:1443-8.
19. Zhang X, Zhang C, Shen S, Xia Yj, Yi L, Gao Q, Wang Y. Dehydroepiandrosterone induces ovarian and uterine hyperfibriosis in female rats. Hum Reprod. 2013;28:3074-85.
20. Miao ZL, Guo L, Wang YX, Cui R, Yang N, Huang MQ, et al. The intervention effect of Rosiglitazone in ovarian fibrosis of PCOS rats. Biomed Environ Sci 2012;25:46-52.
21. Kumar A, Woods KS, Bartolucci AA, Azziz R. Prevalence of adrenal androgen excess in patients with the polycystic ovary syndrome. Clin Endocrinol (Oxf) 2005;62:644-9.
22. Goodarzi MO, Carmina E, Azziz R. DHEA, DHEAS and PCOS. J Steroid Biochem Mol Biol 2015;145:213-25.